Clinical trials for AJOVY
AJOVY was evaluated in three phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group trials, and a long-term extension.
AJOVY was evaluated in HALO—two phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group trials.1,2
As an extension of the HALO trials, AJOVY was further studied in the Long-Term Extension study—a 12-month, multicenter, randomized, double-blind, parallel-group study evaluating monthly and quarterly dosing.2
As the primary purpose of the study was the collection of long-term safety data for patients treated with AJOVY, the study was not placebo controlled.2
AJOVY was also evaluated in FOCUS, a phase 3b, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, evaluating efficacy and safety of quarterly and monthly treatment with AJOVY, compared to placebo in patients with chronic or episodic migraine who had experienced inadequate response to 2–4 classes of prior preventive treatments.3
See efficacy results in clinical trials for AJOVY